Clearpoint Neuro Inc. · NASDAQ:CLPT
Clearpoint Neuro — MRI Interventions — Investor Presentation (October 2017)
27 slides from Clearpoint Neuro's investor presentation, Oct 3, 2017
Slide 1: Investor Presentation October 2017
Investor Presentation October 2017 © 2017 MRI INTERVENTIONS, INC. | 1
Slide 2: Forward Looking Statements
Forward Looking Statements Statements herein concerning MRI Interventions, Inc. (the “Company”) plans, growth and strategies may include forward-looking statements within the context of the federal securities laws. Statements regarding the Company’s future events, developments and future performance
Slide 3: MRIC: The Platform Company for MRI-Guided Therapies
MRIC: The Platform Company for MRI-Guided Therapies MRI Interventions: Leader in the Delivery of MRI-Guided Therapies Primary Innovator in the Field, grown out of the Advanced MR department at Johns Hopkins Extensive Intellectual Property position: 70+ issued US patents, 45 international Proven trac
Slide 4: Why MRI-Guided Therapies?
Why MRI-Guided Therapies? Image-guided Therapeutic Procedures Have Become a Mainstay in U.S. Healthcare 1.2 Million Arthroscopic Procedures 1.5 million Fluoroscopic Procedures 4.0 Million Laparoscopic Procedures MRI Guided Therapeutic Procedures are the Next Step in this Trend Unique capabilities th
Slide 5: Our MRI-Guided Therapy Platform is Currently Being Used to
Our MRI-Guided Therapy Platform is Currently Being Used to: Implant Neuro Stimulation Products from: Medtronic St. Jude Medical NeuroPace Place Laser Ablation Probes from: Medtronic-Visualase Monteris Medical Deliver Drugs and Biologics from: Voyager Medicenna Oxford Biomedica International Stem Cel
Slide 6: Broad and Growing User Base of Leading Neurosurgeons
Broad and Growing User Base of Leading Neurosurgeons ClearPoint ® Is Installed in 50 Top US Hospitals and Growing UC San Francisco San Francisco VA Univ of Michigan Stanford Univ Brigham & Women’s UCSF Benioff Childrens Boston Children’s USC Yale Univ UC San Diego Univ of Pitt Med Center Univ of Col
Slide 7: Foundation of Our Platform: ClearPoint Neuro Navigation System
Foundation of Our Platform: ClearPoint Neuro Navigation System © 2017 MRI INTERVENTIONS, INC. | 7
Slide 8: Without ClearPoint, Minimally Invasive Neuro Procedures Are Performed Blind
Without ClearPoint, Minimally Invasive Neuro Procedures Are Performed “Blind” Conventional Stereotactic Procedure ClearPoint Neuro Procedure No real time images images from earlier in the day or week © 2017 MRI INTERVENTIONS, INC. | 8
Slide 9: ClearPoint Neuro Navigation System: MRI-Guided NeuroSurgical Platform
ClearPoint Neuro Navigation System: MRI-Guided NeuroSurgical Platform ClearPoint Components: Capital Sale Recurring Revenue Reusable Hardware Components Integrated Software Single-Use, Disposable Components Emory University Hospital Univ. of California San Francisco Univ. of Pittsburgh Medical Cente
Slide 10: Details on Our ClearPoint Neuronavigation System Platform
Details on Our ClearPoint Neuronavigation System Platform ClearPoint Procedure Overview: ClearPoint Video ClearPoint Video Entry and Trajectory Alignment and Insertion © 2017 MRI INTERVENTIONS, INC. | 10
Slide 11: Multiple Clinical Applications for Our ClearPoint System Platform
Multiple Clinical Applications for Our ClearPoint System Platform Electrode Placement and Laser Ablation Drug Delivery Significant Unmet Medical Parkinson’s disease, Epilepsy, Brain Tumor, Dystonia Enabling Multiple Therapies from Multiple Companies: Electrode Placement: Medtronic, St. Jude, Neuropa
Slide 12: Strong Business Model for Our Core MRI-Guided Navigation Platform
Strong Business Model for Our Core MRI-Guided Navigation Platform ClearPoint Hardware/Software: $100,000 - $150,000 ASP ClearPoint Disposables: ~$7,500 ASP per procedure with strong margins Recurring revenue from the sale of disposables Procedures covered by existing inpatient DRG reimbursement code
Slide 13: ClearPoint Neurosurgical Procedure Growth
ClearPoint Neurosurgical Procedure Growth 800 Procedures 650-700 CAGR, 2013 2016: 46% 700 600 Q1, 2017: 146 500 Procedures 400 Q2, 2017: 162 Procedures 300 Nine quarters in a 200 row of procedure 100 growth 0 2013 2014 2015 2016 2017 Outlook © 2017 MRI INTERVENTIONS, INC. | 13
Slide 14: Expanding Our Platform: New Procedural Applications
Expanding Our Platform: New Procedural Applications © 2017 MRI INTERVENTIONS, INC. | 14
Slide 15: Expanding MRIC's MRI-Guided Therapy Platform Benefits Larger Patient Populations
Expanding MRIC’s MRI-Guided Therapy Platform Benefits Larger Patient Populations First, MRIC established the Capability of the Platform… Began with Electrode Placement (DBS) Parkinson’s disease, dystonia Expanded to Biopsy Brain Tumor Expanded to Laser Ablation Probe Placement Epilepsy and Brain Tum
Slide 16: Expanding into the Stroke Market
Expanding into the Stroke Market Leveraging Existing Capabilities and Install Base Expanding the Reach of the MRIC Platform into the Stroke Market Joint Development Agreement with Mayo Clinic Dr. Bernard Bendok, Chair of Neurosurgery, Mayo Arizona Large Stroke Market 5th leading cause of death in US
Slide 17: Our MRI-Guided Approach to Intra Cerebral Hemorrhagic Stroke
Our MRI-Guided Approach to Intra Cerebral Hemorrhagic Stroke Current Approaches for Hemorrhage Removal and Decompression are Inadequate: Open craniotomy provides visibility but is highly invasive, destroys brain tissue Minimally Invasive approach has very limited ability to quantify volume reduction
Slide 18: Expanding our Platform with a Novel Ablation Technology
Expanding our Platform with a Novel Ablation Technology Co-Development Agreement Will Add Additional Capabilities License and Co-Development Agreement with Acoustic MedSystems (AMS) Leading developer of ultrasound ablation technologies and systems Base technology has 510k clearance Initial license a
Slide 19: Co-Development Focused First on Pancreatic Cancer Market
Co-Development Focused First on Pancreatic Cancer Market Pancreatic Cancer Market Major Unmet Medical Need 50,000 patients in US diagnosed annually 10,000 to 15,000 cases annually are localized, non-metastatic tumors, but untreatable because of the tumor location Our Therapeutic Approach Targets Unt
Slide 20: Strong Pipeline of New Products to Add to our Existing Products
Strong Pipeline of New Products to Add to our Existing Products Leveraging our MRI-Guided Therapy Platform Projected Development Pipeline 2017 2018 Q2 Q3 Q4 Q1 Q2 Q3 Q4 New Products in Development ClearPoint Software 2.0 ClearPoint Drug Delivery Cannula CE Mark - - - - - - - - - - - - -- ClearPoint
Slide 21: Addressable Markets for our MRI-Guided Therapy Platform
Addressable Markets for our MRI-Guided Therapy Platform Functional Neurosurgery Market Stroke Oncology Drug Delivery Market Parkinsons Epilepsy Brain Tumor ICH Pancreas Parkinson’s Brian Tumor Prevalence 1,500,000 2,200,000 80,000 90,000 50,000 1,500,000 80,000 Annual Potential 12,500 28,000 15,000
Slide 22: Financials
Financials © 2017 MRI INTERVENTIONS, INC. | 22
Slide 23: Revenue Growth Accelerating
Revenue Growth Accelerating… $7,000,000 Total Revenue Total CAGR since 2014: 26 % $6,000,000 Disposable Product CAGR: 35 % $5,000,000 $4,000,000 Other Results of Note: 9 Quarters in a row of increasing $3,000,000 procedures as of Q2, 2017 Installed at 50 of 250+ target US $2,000,000 neurosurgery cen
Slide 24: Cash Flow From Operations
Cash Flow From Operations*: 2015 Q2, 2017 $0 Q1 Q2 Q3 Q4 Q1 Q22 Q32 Q42 Q12 Q2 -$500,000 -$1,000,000 -$1,500,000 -$2,000,000 -$2,500,000 -$3,000,000 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Forecast 2015 2016 2017 *Excludes interest payments, non-cash compensation and financing costs © 2017 MRI INTERVENTIONS,
Slide 25: Income Statement, Last Quarters
Income Statement, Last 5 Quarters Quarter Ended Jun-16 Sep-16 Dec-16 Mar-17 Jun-17 Revenues: Disposable product revenues $ 1,030 $ 1,272 $ 1,363 $ 1,663 $ 1,434 Reusable product revenues 37 309 224 259 459 Total product revenues 1,067 1,581 1,587 1,922 1,893 Service revenues 37 35 48 85 83 Total rev
Slide 26: Experienced Medical Device Management Team
Experienced Medical Device Management Team Management Team Frank Grillo CEO Peter Piferi COO Wendelin Maners VP Sales & Mrktg Hal Hurwitz CFO Board of Directors Kimble Jenkins, Maria Sainz John Fletcher Pascal Girin Timothy Frank Grillo, Chairman Richards CEO Managing Partner, Founder Jack Spencer 2
Slide 27: Summary
Summary Significant Value in Owning the MRI-Guided Therapy Platform Leader in this Field - Primary Innovator, Established Clinical Footprint, Industry Integration, IP World-Class Research Institutions Behind All Major Initiatives Proven Ability to Develop, Commercialize and Secure Clinical Adoption
MRI Interventions — Investor Presentation (October 2017) on 6ix